About Oric Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://oricpharma.com/
Frequently Asked Questions
What is the 52-week range for ORIC?
The 52-week high is $14.93 and the 52-week low is $7.23.
What is the P/E ratio for ORIC?
The P/E ratio data is currently unavailable.
What is the dividend yield for ORIC?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -35.35%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.07.
Analyst Recommendation Trends
Wall Street analyst consensus for ORIC over the last few months:
Latest ORIC News
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2026 (the “Grant Date”), ORIC granted a total of 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive employees who began their employment with ORIC in September 2026. These inducement g
BTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26
BTIG analyst Jeet Mukherjee initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and announces Price Target of $26.
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ORIC Pharmaceuticals, Inc. (ORIC) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 10:00 AM EDTCompany ParticipantsJacob Chacko -...
ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch
On August 3, ORIC Pharmaceuticals (NASDAQ:ORIC) reported second-quarter results that showed a clinical-stage biotech converting years of early work into two separate late-stage bets at once. The company started Himalayas-1, a global Phase 3 trial of its lead prostate cancer drug rinzimetostat, while holding $387.6 million in cash and investments to fund the effort. That […]
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-28 | Piscitelli Dominic | -13,400 | - | - |
| 2026-09-28 | Piscitelli Dominic | -13,400 | $13.5267 | $181,258 |
| 2026-09-28 | Piscitelli Dominic | +13,400 | $4.36 | $58,424 |
| 2026-09-24 | Piscitelli Dominic | -600 | - | - |
| 2026-09-24 | Piscitelli Dominic | -500 | $13.505 | $6,753 |
| 2026-09-24 | Piscitelli Dominic | -100 | $13.5 | $1,350 |
| 2026-09-24 | Piscitelli Dominic | +600 | $4.36 | $2,616 |
| 2026-08-26 | Piscitelli Dominic | -25,000 | - | - |
| 2026-08-26 | Piscitelli Dominic | -52,000 | - | - |
| 2026-08-26 | Piscitelli Dominic | -77,000 | $13.6859 | $1,053,814 |
| 2026-08-26 | Piscitelli Dominic | +25,000 | $6 | $150,000 |
| 2026-08-26 | Piscitelli Dominic | +52,000 | $4.36 | $226,720 |
| 2026-07-24 | Heyman Richard A. | -3,500 | - | - |
| 2026-07-24 | Heyman Richard A. | -6,100 | $12.02 | $73,322 |
| 2026-07-24 | Heyman Richard A. | -7,000 | $12.02 | $84,140 |
| 2026-07-24 | Heyman Richard A. | +3,500 | $1.6 | $5,600 |
| 2026-07-06 | Heyman Richard A. | -300 | $12 | $3,600 |
| 2026-02-24 | Piscitelli Dominic | -52,000 | - | - |
| 2026-02-24 | Piscitelli Dominic | -52,000 | $13.5132 | $702,686 |
| 2026-02-24 | Piscitelli Dominic | +52,000 | $4.36 | $226,720 |
| 2026-01-16 | Heyman Richard A. | -3,200 | $12.0046 | $38,415 |
| 2026-01-16 | Heyman Richard A. | -3,500 | $12.0046 | $42,016 |
| 2026-01-02 | Piscitelli Dominic | +34,500 | - | - |
| 2026-01-02 | Piscitelli Dominic | +206,500 | - | - |
| 2026-01-02 | You Angie | +40,000 | - | - |
| 2026-01-02 | Chacko Jacob | +112,500 | - | - |
| 2026-01-02 | Chacko Jacob | +675,000 | - | - |
| 2026-01-02 | Multani Pratik S | +35,500 | - | - |
| 2026-01-02 | Multani Pratik S | +214,000 | - | - |
| 2026-01-02 | Heyman Richard A. | +40,000 | - | - |
| 2026-01-02 | Dier Mardi | +40,000 | - | - |
| 2026-01-02 | Kunkel Lori Anne | +40,000 | - | - |
| 2026-01-02 | Hoerter Steven L. | +40,000 | - | - |
| 2025-12-16 | Piscitelli Dominic | -10,720 | $9.0604 | $97,127 |
| 2025-12-16 | Chacko Jacob | -33,374 | $9.06 | $302,368 |
| 2025-12-16 | Multani Pratik S | -10,720 | $9.0605 | $97,129 |
| 2025-12-15 | Piscitelli Dominic | -11,333 | - | - |
| 2025-12-15 | Piscitelli Dominic | -10,000 | - | - |
| 2025-12-15 | Piscitelli Dominic | -8,000 | - | - |
| 2025-12-15 | Piscitelli Dominic | +29,333 | - | - |
| 2025-12-15 | Chacko Jacob | -33,333 | - | - |
| 2025-12-15 | Chacko Jacob | -28,333 | - | - |
| 2025-12-15 | Chacko Jacob | -22,000 | - | - |
| 2025-12-15 | Chacko Jacob | +83,666 | - | - |
| 2025-12-15 | Multani Pratik S | -11,333 | - | - |
| 2025-12-15 | Multani Pratik S | -10,000 | - | - |
| 2025-12-15 | Multani Pratik S | -8,000 | - | - |
| 2025-12-15 | Multani Pratik S | +29,333 | - | - |
| 2025-12-08 | Kunkel Lori Anne | -10,000 | - | - |
| 2025-12-08 | Kunkel Lori Anne | +10,000 | $7.9 | $79,000 |
| 2025-12-04 | Kunkel Lori Anne | -5,534 | - | - |
| 2025-12-04 | Kunkel Lori Anne | +5,534 | $3.75 | $20,753 |
| 2025-10-06 | Piscitelli Dominic | -11,000 | - | - |
| 2025-10-06 | Piscitelli Dominic | -11,000 | $14.5199 | $159,719 |
| 2025-10-06 | Piscitelli Dominic | +11,000 | $4.36 | $47,960 |
| 2025-10-06 | Chacko Jacob | -37,461 | $12.32 | $461,520 |
| 2025-10-03 | Heyman Richard A. | -1,447 | - | - |
| 2025-10-03 | Heyman Richard A. | -18,125 | - | - |
| 2025-10-03 | Heyman Richard A. | -13,228 | - | - |
| 2025-10-03 | Heyman Richard A. | +1,447 | $3.75 | $5,426 |
| 2025-10-03 | Heyman Richard A. | +31,353 | $1.6 | $50,165 |